Cagrilintide — compound monograph
Long-acting amylin and calcitonin receptor agonist (acylated). Phase 3. The Institute assesses 2 outcomes for this compound and grades the strongest at moderate certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Cagrilintide
- Compound class
- Long-acting amylin and calcitonin receptor agonist (acylated)
- Assessment series
- Amylin analogues
- Synonyms and codes
- AM833 · NNC0174-0833 · cagrilintide (INN)
- Route as evaluated
- Subcutaneous once weekly
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 1415456-99-1
- Molecular formula
- not published in full
- Average mass
- ≈3751 (reported approximate)
- Monoisotopic mass
- not published
- ATC classification
- not assigned
§1.3Sequence and structural notes
Native human amylin is amyloidogenic and unsuitable as a therapeutic. Cagrilintide substitutes residues in the amyloid-prone 20–29 region, in the manner established by pramlintide, and adds a lipidation handle for weekly dosing.
§1.4Assessment status
The Institute assesses Cagrilintide across 2 indications and grades the strongest of them at moderate certainty. In confirmatory clinical development; no marketing authorisation.
Table 1. Assessed outcomes for Cagrilintide, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Obesity and overweight in adults | −10.8 % body weight at 26 weeks with cagrilintide 4.5 mg monotherapy versus −3.0 % with placebo, and −8.6 % with liraglutide 3.0 mg as active… | Moderate | 2 |
| Type 2 diabetes mellitus | Combination with semaglutide 2.4 mg gave −15.6 % weight and −2.2 % HbA1c at 32 weeks | Low | 1 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.